Citigroup Boosts Humana (NYSE:HUM) Price Target to $350.00

Humana (NYSE:HUM) had its price objective lifted by equities research analysts at Citigroup from $340.00 to $350.00 in a report issued on Thursday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the insurance provider’s stock. Citigroup‘s target price would suggest a potential upside of 10.21% from the company’s current price.

A number of other equities analysts also recently weighed in on HUM. UBS Group boosted their price target on Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a research report on Thursday, August 1st. BMO Capital Markets downgraded Humana from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $345.00 to $290.00 in a research report on Monday, September 30th. Canaccord Genuity reissued a “buy” rating on shares of Humana in a research report on Monday, October 21st. Cantor Fitzgerald raised Humana from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $300.00 to $345.00 in a research report on Monday, August 12th. Finally, SunTrust Banks boosted their price target on Humana to $335.00 and gave the stock a “hold” rating in a research report on Thursday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company. Humana has a consensus rating of “Buy” and a consensus target price of $322.63.

Shares of NYSE:HUM traded up $2.44 during midday trading on Thursday, reaching $317.58. The company had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The business’s 50 day moving average price is $277.48 and its 200 day moving average price is $270.93. The stock has a market cap of $39.82 billion, a PE ratio of 21.83, a P/E/G ratio of 1.27 and a beta of 0.85. Humana has a 1-year low of $225.65 and a 1-year high of $342.03.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, topping analysts’ consensus estimates of $4.58 by $0.45. The firm had revenue of $16.24 billion for the quarter, compared to the consensus estimate of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.58 earnings per share. On average, research analysts expect that Humana will post 17.75 earnings per share for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the transaction, the insider now owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.54% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Endurance Wealth Management Inc. grew its position in shares of Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after purchasing an additional 78 shares during the last quarter. Whittier Trust Co. acquired a new position in shares of Humana in the second quarter valued at approximately $27,000. Next Capital Management LLC acquired a new position in shares of Humana in the second quarter valued at approximately $27,000. Quest Capital Management Inc. ADV acquired a new position in shares of Humana in the third quarter valued at approximately $30,000. Finally, Advantage Investment Management LLC grew its position in shares of Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 89 shares during the last quarter. 92.93% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Convertible Shares

Stock Target Advisor

Analyst Recommendations for Humana (NYSE:HUM)

Leave a Reply

Your email address will not be published. Required fields are marked *

*